Yu LX - Search Results

1

A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.

Jiang W, Makhlouf F, Schuirmann DJ, Zhang X, Zheng N, Conner D, Yu LX, Lionberger R. Jiang W, et al. Among authors: yu lx. AAPS J. 2015 Jul;17(4):891-901. doi: 10.1208/s12248-015-9753-5. Epub 2015 Apr 4. AAPS J. 2015. PMID: 25840883 Free PMC article.

2

Biopharmaceutics classification system: the scientific basis for biowaiver extensions.

Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. Yu LX, et al. Pharm Res. 2002 Jul;19(7):921-5. doi: 10.1023/a:1016473601633. Pharm Res. 2002. PMID: 12180542 Free article.

3

Applications of process analytical technology to crystallization processes.

Yu LX, Lionberger RA, Raw AS, D'Costa R, Wu H, Hussain AS. Yu LX, et al. Adv Drug Deliv Rev. 2004 Feb 23;56(3):349-69. doi: 10.1016/j.addr.2003.10.012. Adv Drug Deliv Rev. 2004. PMID: 14962586 Review.

4

The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs.

Yu LX, Straughn AB, Faustino PJ, Yang Y, Parekh A, Ciavarella AB, Asafu-Adjaye E, Mehta MU, Conner DP, Lesko LJ, Hussain AS. Yu LX, et al. Mol Pharm. 2004 Sep-Oct;1(5):357-62. doi: 10.1021/mp0499407. Mol Pharm. 2004. PMID: 16026005 Clinical Trial.

5

Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.

Kwon H, Lionberger RA, Yu LX. Kwon H, et al. Among authors: yu lx. Mol Pharm. 2004 Nov-Dec;1(6):455-65. doi: 10.1021/mp049921x. Mol Pharm. 2004. PMID: 16028357

6

Stability, dose uniformity, and palatability of three counterterrorism drugs-human subject and electronic tongue studies.

Sadrieh N, Brower J, Yu L, Doub W, Straughn A, Machado S, Pelsor F, Martin ES, Moore T, Reepmeyer J, Toler D, Nguyenpho A, Roberts R, Schuirmann DJ, Nasr M, Buhse L. Sadrieh N, et al. Pharm Res. 2005 Oct;22(10):1747-56. doi: 10.1007/s11095-005-6387-x. Epub 2005 Sep 22. Pharm Res. 2005. PMID: 16180133

7

Bioequivalence approaches for highly variable drugs and drug products.

Haidar SH, Davit B, Chen ML, Conner D, Lee L, Li QH, Lionberger R, Makhlouf F, Patel D, Schuirmann DJ, Yu LX. Haidar SH, et al. Among authors: yu lx. Pharm Res. 2008 Jan;25(1):237-41. doi: 10.1007/s11095-007-9434-x. Epub 2007 Sep 22. Pharm Res. 2008. PMID: 17891552 Review.

8

Spreadability measurements to assess structural equivalence (Q3) of topical formulations--a technical note.

Kryscio DR, Sathe PM, Lionberger R, Yu L, Bell MA, Jay M, Hilt JZ. Kryscio DR, et al. AAPS PharmSciTech. 2008;9(1):84-6. doi: 10.1208/s12249-007-9009-5. Epub 2008 Jan 12. AAPS PharmSciTech. 2008. PMID: 18446465 Free PMC article. No abstract available.

9

Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications.

Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, Patel DT, Seo PR, Suh K, Thompson CL, Yu LX. Davit BM, et al. Among authors: yu lx. AAPS J. 2008;10(1):148-56. doi: 10.1208/s12248-008-9015-x. Epub 2008 Mar 5. AAPS J. 2008. PMID: 18446515 Free PMC article.

10

Quality by design: concepts for ANDAs.

Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Lionberger RA, et al. Among authors: yu lx. AAPS J. 2008 Jun;10(2):268-76. doi: 10.1208/s12248-008-9026-7. Epub 2008 May 9. AAPS J. 2008. PMID: 18465252 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

373 results

Search Page

Filters